# Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma

Source: https://onco.cc/trials/nct07502287/  
OnCo record `nct07502287` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Fludarabine and Cyclophosphamide in neuroblastoma, run by Beijing Biotech, now recruiting.

## Summary

Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma is a phase 1/2 interventional study registered as NCT07502287 by Beijing Biotech, with 36 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-03-14. Interventions recorded: EB-DTNB-NK, Fludarabine and Cyclophosphamide.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07502287
- Phase: 1/2
- Setting: A Phase 1/Phase 2, Open-Label Study of BiomarkerInformed, Allogeneic Dual-Target GD2/B7-H3 (CD276) CAR-NK Cells in Children and Young Adults With Relapsed or Refractory Neuroblastoma
- Sponsor: Beijing Biotech
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT07502287: https://clinicaltrials.gov/study/NCT07502287

## Connected records

- cancers: [Neuroblastoma (paediatric)](https://onco.cc/cancers/neuroblastoma/)
- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Fludarabine](https://onco.cc/drugs/fludarabine/)

---
JSON: https://onco.cc/api/v1/entities/nct07502287.json